Pharmacoeconomics 2008; 26 (2): 163-178 ORIGINAL RESEARCH ARTICLE 1170-7690/08/0002-0163/$48.00/0 © 2008 Adis Data Information BV. All rights reserved. Non-Traditional Settings for Influenza Vaccination of Adults Costs and Cost Effectiveness Lisa A. Prosser, 1 Megan A. O’Brien, 1 Noelle-Angelique M. Molinari, 2 Katherine H. Hohman, 1 Kristin L. Nichol, 3 Mark L. Messonnier 2 and Tracy A. Lieu 1,4 1 Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, Massachusetts, USA 2 National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA 3 VA Medical Center and University of Minnesota, Minneapolis, Minnesota, USA 4 Division of General Pediatrics, Children’s Hospital, Boston, Massachusetts, USA Objective: Influenza vaccination rates remain far below national goals in the US. Abstract Expanding influenza vaccination in non-traditional settings such as worksites and pharmacies may be a way to enhance vaccination coverage for adults, but scant data exist on the cost effectiveness of this strategy. The aims of this study were to (i) describe the costs of vaccination in non-traditional settings such as pharmacies and mass vaccination clinics; and (ii) evaluate the projected health benefits, costs and cost effectiveness of delivering influenza vaccination to adults of varying ages and risk groups in non-traditional settings compared with scheduled doctor’s office visits. All analyses are from the US societal perspective. Methods: We evaluated the costs of influenza vaccination in non-traditional settings via detailed telephone interviews with representatives of organizations that conduct mass vaccination clinics and pharmacies that use pharmacists to deliver vaccinations. Next, we constructed a decision tree to compare the project- ed health benefits and costs of influenza vaccination delivered via non-traditional settings or during scheduled doctor’s office visits with no vaccination. The target population was stratified by age (18–49, 50–64 and ≥65 years) and risk status (high or low risk for influenza-related complications). Probabilities and costs (direct and opportunity) for uncomplicated influenza illness, outpatient visits, hospitalizations, deaths, vaccination and vaccine adverse events were derived from primary data and from published and unpublished sources. Results: The mean cost (year 2004 values) of vaccination was lower in mass vaccination ($US17.04) and pharmacy ($US11.57) settings than in scheduled doctor’s office visits ($US28.67). Vaccination in non-traditional settings was projected to be cost saving for healthy adults aged ≥50 years, and for high-risk